Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02724-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Sakura Hiraide Taniguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Appendiceal carcinoma (AC) is a rare malignancy and has distinct genomic features, but their impact on prognosis and chemotherapy efficacy requires further investigation.
Methods
This retrospective study analyzed patients with advanced AC from the Japanese nationwide comprehensive genomic profiling test database, the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, focusing on genetic alterations and their associations with clinical outcomes.
Results
Of the 314 patients, the histological types Queryincluded adenocarcinoma (Ad) (51.9%), mucinous adenocarcinoma (MAd) (30.3%), goblet cell adenocarcinoma (12.4%), and signet-ring cell adenocarcinoma (5.4%). The most common mutations were KRAS (52.5%), TP53 (49.4%), SMAD4 (18.8%), and GNAS (17.2%). KRAS mutations were most frequent in MAd (68.4%) and Ad (58.9%), whereas TP53 mutations were mostly prevalent in Ad (62.6%). We classified patients into molecular subtypes based on the presence of mutations and analyzed differences in overall survival (OS) by molecular subtype. Patients with TP53 -mutant (mut) dominant tumors (all TP53 -mut) and KRAS -mut focused tumors ( TP53 -wild-type (wt)/ GNAS -wt/ KRAS -mut/any SMAD4 ) showed a poorer median OS compared with those with GNAS -mut focused tumors ( TP53 -wt/ GNAS -mut/any KRAS /any SMAD4 ) (median 47.4 and 37.5 months vs. not reached; p = 0.01 and p = 0.01, respectively). TP53 mutation was associated with poor time to treatment failure and OS with the oxaliplatin-based regimen for first-line chemotherapy.
Conclusions
This study suggested that the genetic mutations influenced the prognosis and chemotherapy efficacy in AC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, 4-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan. masanobu.takahashi.a7@tohoku.ac.jp.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, 4-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan. masanobu.takahashi.a7@tohoku.ac.jp.
- Clinical Research Data Center, Tohoku University Hospital, Sendai, Japan.
Zitieren
APA
Taniguchi, S. H., Takahashi, M., Chiu, S. W., Komine, K., Wakayama, S., Numakura, R., Yoshida, Y., Kasahara, Y., Ouchi, K., Imai, H., Saijo, K., Shirota, H., & Ishioka, C. (2025). Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02724-2
Vancouver
Taniguchi SH, Takahashi M, Chiu SW, Komine K, Wakayama S, Numakura R, et al. Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02724-2
BibTeX
@article{Taniguchi2025,
author = {Taniguchi, Sakura Hiraide and Takahashi, Masanobu and Chiu, Shih-Wei and Komine, Keigo and Wakayama, Shonosuke and Numakura, Ryunosuke and Yoshida, Yuya and Kasahara, Yuki and Ouchi, Kota and Imai, Hiroo and Saijo, Ken and Shirota, Hidekazu and Ishioka, Chikashi},
title = {Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02724-2}
}
EUVIMED